Peters J, Foord S, Dieguez C, Salvador J, Hall R, Scanlon M F
Clin Endocrinol (Oxf). 1985 Sep;23(3):289-93. doi: 10.1111/j.1365-2265.1985.tb00226.x.
We have studied the effects of the TRH related dipeptide histidyl-proline diketopiperazine [cyclo (His-Pro)] on basal and stimulated TSH and PRL secretion in normal volunteers, in patients with microprolactinomas and in patients with primary hypothyroidism. Cyclo (His-Pro), 400 micrograms intravenously did not alter basal TSH or PRL levels in normal males and females and was also without effect upon the elevated basal TSH and PRL levels in patients with primary hypothyroidism and microprolactinomas respectively. The same dose of cyclo (His-Pro) did not affect the TSH or PRL response to TRH (100 micrograms i.v.) in normal male volunteers. These data indicate that cyclo (His-Pro) does not affect TSH and PRL secretion in man at this dosage. It is also unlikely that this molecule will be of any therapeutic benefit in states of hyperprolactinaemia.
我们研究了促甲状腺激素释放激素（TRH）相关二肽组氨酰 - 脯氨酸二酮哌嗪[环（组 - 脯）]对正常志愿者、微泌乳素瘤患者及原发性甲状腺功能减退症患者基础及刺激状态下促甲状腺激素（TSH）和泌乳素（PRL）分泌的影响。静脉注射400微克环（组 - 脯）对正常男性和女性的基础TSH或PRL水平无影响，对原发性甲状腺功能减退症患者升高的基础TSH水平及微泌乳素瘤患者升高的基础PRL水平也无作用。相同剂量的环（组 - 脯）对正常男性志愿者TSH或PRL对TRH（静脉注射100微克）的反应无影响。这些数据表明，此剂量的环（组 - 脯）对人体TSH和PRL分泌无影响。该分子在高泌乳素血症状态下也不太可能有任何治疗益处。
